Top Markets
#1 Black Phoenix Black Phoenix +829.97%
#2 pipedog pipedog +41.42%
#3 PondCoin PondCoin +34.34%
#4 Bless Bless +32.22%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +28.74%
#6 SAFEcoin SAFEcoin +26.51%
#7 Beam Beam +24.69%
#8 Magma Finance Magma Finance +19.36%
#9 Seeker Seeker +19.26%
#10 YFSX YFSX +16.15%
Coin of the day
Black Phoenix Black Phoenix
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Alpine Immune Sciences, Inc. Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc.

ALPN
Classement en actions #6581
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company... Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.
Prix de l'action
$64.97
Dernière synchronisation: 2024-05-20
Capitalisation boursière
$1.97B
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Alpine Immune Sciences, Inc. (ALPN)

Catégorie

Healthcare
Bénéfices pour Alpine Immune Sciences, Inc. (ALPN)
Bénéfices en Mar 2024 TTM : $-36.73M
Selon les derniers rapports financiers de Alpine Immune Sciences, Inc., les bénéfices actuels de l'entreprise sont de $-36.73M. En 2022, l'entreprise a réalisé un bénéfice de $-55.43M, une diminution par rapport à celui de 2021 qui était de $-50.42M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Alpine Immune Sciences, Inc. de 2012 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
2026 (TTM) $-36.73M 14.50%
2023 $-32.08M -42.13%
2022 $-55.43M 9.94%
2021 $-50.42M 80.42%
2020 $-27.95M -33.23%
2019 $-41.85M 13.56%
2018 $-36.85M 361.64%
2017 $-7.98M -74.63%
2016 $-31.46M 37.89%
2015 $-22.82M 51.76%
2014 $-15.04M -7.17%
2013 $-16.20M 69.21%
2012 $-9.57M 0.00%
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -14,460.11%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -5,410.35%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B 10,833.48%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 8,303.89%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH